Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies
Authors:
Open Access
- 12 December 2021
- journal article
- review article
- Published by Walter de Gruyter GmbH in Archivum Immunologiae et Therapiae Experimentalis
- Vol. 70 (1) , 1-14
Abstract
Technologies required to generate induced pluripotent stem cells (iPSC) were first described 15 years ago, providing a strong impetus to the field of regenerative medicine. In parallel, immunotherapy has finally emerged as a clinically meaningful modality of cancer therapy. In particular, impressive efficacy has been achieved in patients with selected haematological malignancies using ex vivo expanded autologous T cells engineered to express chimeric antigen receptors (CARs). While solid tumours account for over 90% of human cancer, they currently are largely refractory to this therapeutic approach. Nonetheless, given the considerable innovation taking place worldwide in the CAR field, it is likely that effective solutions for common solid tumours will emerge in the near future. Such a development will create significant new challenges in the scalable delivery of these complex, costly and individualised therapies. CAR-engineered immune cell products that originate from iPSCs offer the potential to generate unlimited numbers of homogeneous, standardised cell products in which multiple defined gene modification events have been introduced to ensure safety, potency and reproducibility. Here, we review some of the emerging strategies in use to engineer CAR-expressing iPSC-derived drug products.Keywords
Funding Information
- Leucid Bio
- Medical Research Council (MR/R001936/1)
- British Lung Foundation (MESOUK18-2 INT 1)
- Breast Cancer Now (2018JulPR1104)
- Jon Moulton Charitable Foundation
- Wellcome Trust (104802/Z/14/Z)
This publication has 110 references indexed in Scilit:
- Human Pluripotent Stem Cells Produce Natural Killer Cells That Mediate Anti-HIV-1 Activity by Utilizing Diverse Cellular MechanismsJournal of Virology, 2011
- Epigenetic memory in induced pluripotent stem cellsNature, 2010
- Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cellsJournal of Clinical Investigation, 2010
- Reprogramming of T Cells from Human Peripheral BloodCell Stem Cell, 2010
- Reprogramming of Human Peripheral Blood Cells to Induced Pluripotent Stem CellsCell Stem Cell, 2010
- Nuclear reprogramming to a pluripotent state by three approachesNature, 2010
- Direct Reprogramming of Terminally Differentiated Mature B Lymphocytes to PluripotencyCell, 2008
- Induced Pluripotent Stem Cell Lines Derived from Human Somatic CellsScience, 2007
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Differential synergy of Notch and T cell receptor signaling determines αβ versus γδ lineage fateJournal of Experimental Medicine, 2006